For research use only. Not for therapeutic Use.
Tolterodine (Cat.No:I000995) is an antimuscarinic drug used to treat overactive bladder symptoms, such as urinary urgency, frequency, and incontinence. It works by relaxing the bladder muscles and reducing involuntary contractions. Tolterodine is available in immediate-release and extended-release formulations, providing effective relief for individuals with bladder control issues.
| Catalog Number | I000995 |
| CAS Number | 124937-51-5 |
| Synonyms | 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol |
| Molecular Formula | C22H31NO |
| Purity | ≥95% |
| Target | AChR |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20C |
| Reference | </br>1:Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Herschorn S, Nazir J, Ramos B, Hakimi Z.Can Urol Assoc J. 2017 Mar-Apr;11(3-4):123-130. doi: 10.5489/cuaj.4114. PMID: 28515812 </br>2:Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study. Hsiao SM, Chang TC, Chen CH, Wu WY, Lin HH.Low Urin Tract Symptoms. 2017 Apr 23. doi: 10.1111/luts.12167. [Epub ahead of print] PMID: 28436145 </br>3:Tolterodine Tartrate. Ananchenko G, Novakovic J.Profiles Drug Subst Excip Relat Methodol. 2017;42:339-403. doi: 10.1016/bs.podrm.2017.02.007. Epub 2017 Mar 30. PMID: 28431780 </br>4:Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Bray R, Cartwright R, Cardozo L, Hill S, Guan Z, Khullar V.Neurourol Urodyn. 2017 Apr 13. doi: 10.1002/nau.23281. [Epub ahead of print] PMID: 28407338 </br>5:Role of tolterodine in the management of postoperative catheter-related bladder discomfort: Findings in a Nigerian teaching hospital. Tijani KH, Akanmu NO, Olatosi JO, Ojewola RW.Niger J Clin Pract. 2017 Apr;20(4):484-488. doi: 10.4103/1119-3077.196036. PMID: 28406132 Free Article</br>6:Effects of Tamsulosin and Tolterodine on double J stent-related symptoms: A double-blind, randomized, placebo-controlled trial. Moradi M, Abdi H, Ebrahimi S, Rezaee H, Kaseb K.SAGE Open Med. 2017 Feb 28;5:2050312117696436. doi: 10.1177/2050312117696436. eCollection 2017. PMID: 28344784 Free PMC Article</br>7:The effect of extended release tolterodine used for overactive bladder treatment on female sexual function. Zachariou A, Filiponi M.Int Braz J Urol. 2017 Feb 15;43. doi: 10.1590/S1677-5538.IBJU.2016.0303. [Epub ahead of print] PMID: 28199076 </br>8:Histopathologic and Urodynamic Effects of the Anticholinergic Drugs Oxybutynin, Tolterodine, and Trospium on the Bladder. Orgen S, Deliktas H, Sahin H, Gedik A, Nergis Y.Low Urin Tract Symptoms. 2017 Jan;9(1):52-56. doi: 10.1111/luts.12096. Epub 2015 Mar 6. PMID: 28120444 </br>9:Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro. Wang H, Dai DP, Sun P, Xu LP, Liang BQ, Cai JP, Hu GX.Chem Biol Interact. 2017 Feb 25;264:10-15. doi: 10.1016/j.cbi.2017.01.003. Epub 2017 Jan 10. PMID: 28087463 </br>10:Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial. Cai JL, Zhou Z, Yang Y, Yan YF, Jing S, Na YQ.Chin Med J (Engl). 2016 Dec 20;129(24):2899-2906. doi: 10.4103/0366-6999.195461. PMID: 27958220 Free PMC Article |
